Neoantigen-directed therapeutics in the clinic: where are we?
Neoantigen-directed therapeutics in the clinic: where are we?
复制标题
临床中新抗原导向疗法：我们在哪里？
DOI：
10.1016/j.trecan.2023.02.004
复制
发表时间：
2023
期刊：
影响因子：
18.4
通讯作者：
Ott,PatrickA
中科院分区：
文献类型：
--
作者：
Lybaert,Lien;Thielemans,Kris;Feldman,StevenA;vanderBurg,SjoerdH;Bogaert,Cedric;Ott,PatrickA
在过去的十年中，免疫检查点抑制剂（ICI）和嵌合抗原受体（CAR）T细胞疗法将免疫疗法带到了癌症治疗的最前沿;然而，只有一部分患者受益于目前的方法。新抗原驱动的治疗剂特异性地重定向患者的免疫系统，以使其能够或恢复其识别和消除癌细胞的能力。这种策略的肿瘤特异性使健康和正常细胞免受攻击。与这一概念相一致，初步临床试验已经证明了新抗原导向的个性化疫苗的可行性、安全性和免疫原性。我们回顾新抗原驱动的治疗策略，以及他们的承诺和临床成功的日期。
In the past decade, immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cell therapy have brought immunotherapy to the forefront of cancer treatment; however, only subsets of patients benefit from current approaches. Neoantigen-driven therapeutics specifically redirect the immune system of the patient to enable or reinduce its ability to recognize and eliminate cancer cells. The tumor specificity of this strategy spares healthy and normal cells from being attacked. Consistent with this concept, initial clinical trials have demonstrated the feasibility, safety, and immunogenicity of neoantigen-directed personalized vaccines. We review neoantigen-driven therapy strategies as well as their promise and clinical successes to date.